DualityBio Updates Share Capital After HKD 6.46 Million Buyback and Option Exercise

Bulletin Express06-04

Duality Biotherapeutics, Inc. (DualityBio) disclosed two capital movements dated 4 June 2026:

1. Share Buyback • Repurchased 34,000 ordinary shares on the Hong Kong Stock Exchange, booking all as treasury shares. • Transaction price ranged between HKD 186.30 and HKD 201.80, with total consideration of HKD 6.46 million (volume-weighted average price: HKD 189.58). • The repurchases were executed under the mandate approved on 20 June 2025, which authorises up to 8.80 million shares. Cumulative buybacks since then stand at 255,400 shares, representing 0.29 % of the company’s issued share base on the mandate date. A 30-day moratorium on new share issues or treasury-share sales extends to 4 July 2026.

2. Option Exercise • A director exercised options granted under the Pre-IPO Equity Incentive Plan, leading to the issuance of 10,100 new shares at HKD 192.23 per share.

Share Capital Snapshot (as of 4 June 2026) • Issued shares (excluding treasury): 90.38 million, down 0.03 % from 90.40 million on 3 June 2026. • Treasury shares: 255,400. • Total issued shares (including treasury): 90.63 million.

The Cayman-incorporated biotechnology firm confirmed all transactions complied with Hong Kong listing rules and the previously published explanatory statement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191553772?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191553772","market":"us","top_or_hot":-1,"title":"DualityBio Updates Share Capital After HKD 6.46 Million Buyback and Option Exercise","media":"Bulletin Express","content":"<p>Duality Biotherapeutics, Inc. (DualityBio) disclosed two capital movements dated 4 June 2026:</p>\n<p>1. Share Buyback  \n• Repurchased 34,000 ordinary shares on the Hong Kong Stock Exchange, booking all as treasury shares.  \n• Transaction price ranged between HKD 186.30 and HKD 201.80, with total consideration of HKD 6.46 million (volume-weighted average price: HKD 189.58).  \n• The repurchases were executed under the mandate approved on 20 June 2025, which authorises up to 8.80 million shares. Cumulative buybacks since then stand at 255,400 shares, representing 0.29 % of the company’s issued share base on the mandate date. A 30-day moratorium on new share issues or treasury-share sales extends to 4 July 2026.</p>\n<p>2. Option Exercise  \n• A director exercised options granted under the Pre-IPO Equity Incentive Plan, leading to the issuance of 10,100 new shares at HKD 192.23 per share.</p>\n<p>Share Capital Snapshot (as of 4 June 2026)  \n• Issued shares (excluding treasury): 90.38 million, down 0.03 % from 90.40 million on 3 June 2026.  \n• Treasury shares: 255,400.  \n• Total issued shares (including treasury): 90.63 million.</p>\n<p>The Cayman-incorporated biotechnology firm confirmed all transactions complied with Hong Kong listing rules and the previously published explanatory statement.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DualityBio Updates Share Capital After HKD 6.46 Million Buyback and Option Exercise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDualityBio Updates Share Capital After HKD 6.46 Million Buyback and Option Exercise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-04 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Duality Biotherapeutics, Inc. (DualityBio) disclosed two capital movements dated 4 June 2026:</p>\n<p>1. Share Buyback  \n• Repurchased 34,000 ordinary shares on the Hong Kong Stock Exchange, booking all as treasury shares.  \n• Transaction price ranged between HKD 186.30 and HKD 201.80, with total consideration of HKD 6.46 million (volume-weighted average price: HKD 189.58).  \n• The repurchases were executed under the mandate approved on 20 June 2025, which authorises up to 8.80 million shares. Cumulative buybacks since then stand at 255,400 shares, representing 0.29 % of the company’s issued share base on the mandate date. A 30-day moratorium on new share issues or treasury-share sales extends to 4 July 2026.</p>\n<p>2. Option Exercise  \n• A director exercised options granted under the Pre-IPO Equity Incentive Plan, leading to the issuance of 10,100 new shares at HKD 192.23 per share.</p>\n<p>Share Capital Snapshot (as of 4 June 2026)  \n• Issued shares (excluding treasury): 90.38 million, down 0.03 % from 90.40 million on 3 June 2026.  \n• Treasury shares: 255,400.  \n• Total issued shares (including treasury): 90.63 million.</p>\n<p>The Cayman-incorporated biotechnology firm confirmed all transactions complied with Hong Kong listing rules and the previously published explanatory statement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1191553772","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191553772","pubTimestamp":1780573401,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Duality Biotherapeutics, Inc. (DualityBio) disclosed two capital movements dated 4 June 2026: 1. Share Buyback   • Repurchased 34,000 ordinary shares on the Hong Kong Stock Exchange, booking all as...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"DualityBio在646万港元回购和行使期权后更新股本","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"Duality Biotherapeutics, Inc. (DualityBio) disclosed two capital movements dated 4 June 2026:\n1. Share Buyback  \n• Repurchased 34,000 ordinary shares on the Hong Kong Stock Exchange, booking all as treasury shares.  \n• Transaction price ranged between HKD 186.30 and HKD 201.80, with total consideration of HKD 6.46 million (volume-weighted average price: HKD 189.58).  \n• The repurchases were executed under the mandate approved on 20 June 2025, which authorises up to 8.80 million shares. Cumulative buybacks since then stand at 255,400 shares, representing 0.29 % of the company’s issued share base on the mandate date. A 30-day moratorium on new share issues or treasury-share sales extends to 4 July 2026.\n2. Option Exercise  \n• A director exercised options granted under the Pre-IPO Equity Incentive Plan, leading to the issuance of 10,100 new shares at HKD 192.23 per share.\nShare Capital Snapshot (as of 4 June 2026)  \n• Issued shares (excluding treasury): 90.38 million, down 0.03 % from 90.40 million on 3 June 2026.  \n• Treasury shares: 255,400.  \n• Total issued shares (including treasury): 90.63 million.\nThe Cayman-incorporated biotechnology firm confirmed all transactions complied with Hong Kong listing rules and the previously published explanatory statement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191553772","isCrawlerRequest":true}